{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T03:35:14Z","timestamp":1769830514256,"version":"3.49.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["955756"],"award-info":[{"award-number":["955756"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.xphs.2024.10.030","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T16:31:04Z","timestamp":1729701064000},"page":"644-659","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Biowaiver monographs for immediate-release solid oral dosage forms: Lemborexant"],"prefix":"10.1016","volume":"114","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7918-0865","authenticated-orcid":false,"given":"Kristian","family":"Beran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertil","family":"Abrahamsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2519-1179","authenticated-orcid":false,"given":"Naseem","family":"Charoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo","family":"Cristofoletti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4894-7765","authenticated-orcid":false,"given":"Ren\u00e9","family":"Holm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2957-6287","authenticated-orcid":false,"given":"Atsushi","family":"Kambayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Langguth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehul","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Parr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5274-4314","authenticated-orcid":false,"given":"James E.","family":"Polli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinod P.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Dressman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2024.10.030_bib0001","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH Harmonised Guideline. Biopharmaceutics classification system-based biowaivers M9. Available at: https:\/\/www.ich.org\/page\/multidisciplinary-guidelines. Accessed April 11, 2024."},{"key":"10.1016\/j.xphs.2024.10.030_bib0002","doi-asserted-by":"crossref","unstructured":"Beran K, Abrahamsson B, Charoo N, et al. Biowaiver monographs for immediate-release solid oral dosage forms: Voriconazole. 2024 (submitted to JPharmSci, in review)","DOI":"10.1016\/j.xphs.2024.10.055"},{"issue":"7","key":"10.1016\/j.xphs.2024.10.030_bib0003","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1023\/A:1016473601633","article-title":"Biopharmaceutics classification system: the scientific basis for biowaiver extensions","volume":"19","author":"Yu","year":"2002","journal-title":"Pharm Res"},{"issue":"3","key":"10.1016\/j.xphs.2024.10.030_bib0004","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1023\/A:1016212804288","article-title":"A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability","volume":"12","author":"Amidon","year":"1995","journal-title":"Pharm Res"},{"issue":"8","key":"10.1016\/j.xphs.2024.10.030_bib0005","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1016\/j.xphs.2018.03.030","article-title":"A refined developability classification system","volume":"107","author":"Rosenberger","year":"2018","journal-title":"J Pharm Sci"},{"issue":"3","key":"10.1016\/j.xphs.2024.10.030_bib0006","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.xphs.2018.10.044","article-title":"Application of a refined developability classification system","volume":"108","author":"Rosenberger","year":"2019","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2024.10.030_bib0007","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.xphs.2023.11.005","article-title":"Biowaiver monograph for immediate-release solid oral dosage forms: isavuconazonium sulfate","volume":"113","author":"Plano","year":"2024","journal-title":"J Pharm Sci"},{"issue":"4","key":"10.1016\/j.xphs.2024.10.030_bib0008","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.xphs.2022.12.021","article-title":"Biowaiver monograph for immediate-release solid oral dosage forms: levocetirizine dihydrochloride","volume":"112","author":"Charoo","year":"2023","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2024.10.030_bib0009","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.xphs.2021.09.031","article-title":"Biowaiver monograph for immediate-release solid oral dosage forms: sitagliptin phosphate monohydrate","volume":"111","author":"Charoo","year":"2022","journal-title":"J Pharm Sci"},{"issue":"7","key":"10.1016\/j.xphs.2024.10.030_bib0010","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.3390\/pharmaceutics15071909","article-title":"Projection of target drug particle size in oral formulations using the refined developability classification system (rDCS)","volume":"15","author":"Beran","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.xphs.2024.10.030_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.xphs.2024.09.022","article-title":"Using the refined developability classification system (rDCS) to guide the design of oral formulations","author":"Beran","year":"2024","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2024.10.030_bib0012","series-title":"European Pharmacopeia","year":"2016"},{"key":"10.1016\/j.xphs.2024.10.030_bib0013","unstructured":"Eisai Inc. Prescribing Information, DAYVIGO\u00ae (lemborexant) tablets, for oral use. Available at: https:\/\/www.dayvigo.com\/. Accessed 24 September 2024."},{"key":"10.1016\/j.xphs.2024.10.030_bib0014","unstructured":"Biorelevant.com. Biorelevant media prep tool. Available at: https:\/\/biorelevant.com\/?filters=product_type\u2013biorelevant%20media#media_prep_tool_tab. Accessed May 25, 2022."},{"issue":"9","key":"10.1016\/j.xphs.2024.10.030_bib0015","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1016\/j.xphs.2024.06.014","article-title":"A Stratified analysis of supersaturation and precipitation effects based on the refined developability classification system (rDCS)","volume":"113","author":"Beran","year":"2024","journal-title":"J Pharm Sci"},{"issue":"14","key":"10.1016\/j.xphs.2024.10.030_bib0016","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph19148353","article-title":"Physiological role of orexinergic system for health","volume":"19","author":"Villano","year":"2022","journal-title":"Int J Environ Res Public Health"},{"issue":"11","key":"10.1016\/j.xphs.2024.10.030_bib0017","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1021\/acs.jmedchem.5b00217","article-title":"Discovery of (1R,2S)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide (E2006): a potent and efficacious oral orexin receptor antagonist","volume":"58","author":"Yoshida","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.xphs.2024.10.030_bib0018","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3389\/fnins.2020.00691","article-title":"Evolution of orexin neuropeptide system: structure and function","volume":"14","author":"Soya","year":"2020","journal-title":"Front Neurosci"},{"issue":"5","key":"10.1016\/j.xphs.2024.10.030_bib0019","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.conb.2013.04.007","article-title":"Orexin deficiency and narcolepsy","volume":"23","author":"Sakurai","year":"2013","journal-title":"Curr Opin Neurobiol"},{"key":"10.1016\/j.xphs.2024.10.030_bib0020","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.peptides.2016.12.008","article-title":"Increased plasma orexin-A levels in patients with insomnia disorder are not associated with prepro-orexin or orexin receptor gene polymorphisms","volume":"88","author":"Tang","year":"2017","journal-title":"Peptides"},{"issue":"2","key":"10.1016\/j.xphs.2024.10.030_bib0021","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/cpdd.817","article-title":"Pharmacokinetics, pharmacodynamics, and safety of the dual orexin receptor antagonist lemborexant: findings from single-dose and multiple-ascending-dose phase 1 studies in healthy adults","volume":"10","author":"Landry","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.xphs.2024.10.030_bib0022","unstructured":"Eisai Australia Pty. Ltd. Australian product information - Dayvigo\u00ae (lemborexant) film coated tablets. 2023."},{"issue":"5","key":"10.1016\/j.xphs.2024.10.030_bib0023","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1021\/mp500022u","article-title":"Intragastric volume changes after intake of a high-caloric, high-fat standard breakfast in healthy human subjects investigated by MRI","volume":"11","author":"Koziolek","year":"2014","journal-title":"Mol Pharm"},{"issue":"9","key":"10.1016\/j.xphs.2024.10.030_bib0024","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0108467","article-title":"Consuming more of daily caloric intake at dinner predisposes to obesity. A 6-year population-based prospective cohort study","volume":"9","author":"Bo","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.xphs.2024.10.030_bib0025","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1124\/dmd.120.000229","article-title":"Disposition and metabolism of [14C]lemborexant in healthy human subjects and characterization of its circulating metabolites","volume":"49","author":"Ueno","year":"2021","journal-title":"Drug Metabolism Disposition"},{"issue":"1","key":"10.1016\/j.xphs.2024.10.030_bib0026","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/00325481.2020.1823724","article-title":"Lack of residual morning effects of lemborexant treatment for insomnia: summary of findings across 9 clinical trials","volume":"133","author":"Moline","year":"2021","journal-title":"Postgrad Med"},{"key":"10.1016\/j.xphs.2024.10.030_bib0027","unstructured":"Food and Drug Administration (FDA). Draft guidance on lemborexant. 2021."},{"key":"10.1016\/j.xphs.2024.10.030_bib0028","unstructured":"Food and Drug Administration (FDA). Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an abbreviated new drug application. Guidance for industry (draft guidance). Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/bioequivalence-studies-pharmacokinetic-endpoints-drugs-submitted-under-abbreviated-new-drug. Accessed April 11, 2024."},{"key":"10.1016\/j.xphs.2024.10.030_bib0029","unstructured":"Department of Justice. Drug enforcement administration. Rules and regulations. Schedules of controlled substances: placement of lemborexant in schedule IV Vol 86. 2021:12257\u201312260."},{"key":"10.1016\/j.xphs.2024.10.030_bib0030","unstructured":"Eisai Co. Ltd. DAYVIGO approval status worldwide (country\/region) 2023."},{"key":"10.1016\/j.xphs.2024.10.030_bib0031","unstructured":"Eisai Ltd. Product monograph including patient medication information. PrDAYVIGO\u2122. Lemborexant Tablet. Tablet, 5 mg, 10 mg, Oral. House Standard. 2023."},{"key":"10.1016\/j.xphs.2024.10.030_bib0032","unstructured":"Pharmaceuticals and Medical Devices Agency (PMDA). New Drugs Approved in FY 2019. Available at: https:\/\/www.pmda.go.jp\/files\/000235289.pdf."},{"key":"10.1016\/j.xphs.2024.10.030_bib0033","unstructured":"Food and Drug Administration (FDA). Product Quality Review(s) (Lemborexant Tablets 5 mg, 10 mg). Application number: 212028Orig1s000. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/212028Orig1s000TOC.cfm Accessed 24 September 2024."},{"key":"10.1016\/j.xphs.2024.10.030_bib0034","unstructured":"Pharmaceuticals and Medical Devices Agency (PMDA). Report on the deliberation results (Dayvigo Tablets). 2019."},{"key":"10.1016\/j.xphs.2024.10.030_bib0035","unstructured":"Minhua Chen YZ, Chunxiang Huang, Xiaoyu Zhang. Crystalline form of orexin receptor antagonist, processes for preparation thereof and use thereof. Vol US 2020\/0190060 A1. C07D 401\/12 ed.; 2020."},{"issue":"5","key":"10.1016\/j.xphs.2024.10.030_bib0036","first-page":"455","article-title":"Physiologically-based pharmacokinetic modeling to predict drug interactions of lemborexant with CYP3A inhibitors. CPT: Pharmacometrics &amp","volume":"10","author":"Ueno","year":"2021","journal-title":"Syst Pharmacol"},{"key":"10.1016\/j.xphs.2024.10.030_bib0037","unstructured":"Food and Drug Administration (FDA). NDA 212028 multi-discipline review and evaluation, DAYVIGO (lemborexant). Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/212028Orig1s000TOC.cfm"},{"issue":"12","key":"10.1016\/j.xphs.2024.10.030_bib0038","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1002\/jcph.1683","article-title":"Population pharmacokinetics and exposure-response analyses for the most frequent adverse events following treatment with lemborexant, an orexin receptor antagonist, in subjects with insomnia disorder","volume":"60","author":"Lalovic","year":"2020","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.xphs.2024.10.030_bib0039","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.678","article-title":"Effect of gastric acid-reducing agents on the pharmacokinetics and efficacy of lemborexant","volume":"8","author":"Landry","year":"2020","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.xphs.2024.10.030_bib0040","unstructured":"Food and Drug Administration (FDA). Guidance for industry. Food-effect bioavailability and fed bioequivalence studies. 2002."},{"key":"10.1016\/j.xphs.2024.10.030_bib0041","unstructured":"Food and Drug Administration (FDA). Guidance document. M12 drug interaction studies (draft guidance). Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/m12-drug-interaction-studies. Accessed April 11, 2024."},{"key":"10.1016\/j.xphs.2024.10.030_bib0042","series-title":"Compositions and Methods for Treating Insomnia","author":"Moline","year":"2019"},{"key":"10.1016\/j.xphs.2024.10.030_bib0043","unstructured":"Dressman J. unpublished results."},{"key":"10.1016\/j.xphs.2024.10.030_bib0044","series-title":"Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation","article-title":"Scale-up and postapproval changes: chemistry, manufacturing, and controls","year":"1995"},{"key":"10.1016\/j.xphs.2024.10.030_bib0045","unstructured":"Abe T, Ayata Y, Suzuki N, et al. Drug substance of lemborexant and medicinal composition comprising same. 2022."},{"key":"10.1016\/j.xphs.2024.10.030_bib0046","unstructured":"FDA Dissolution Methods Database Available at: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/dissolution\/dsp_SearchResults.cfm. Accessed 27 January."},{"issue":"12","key":"10.1016\/j.xphs.2024.10.030_bib0047","doi-asserted-by":"crossref","first-page":"4940","DOI":"10.1002\/jps.22217","article-title":"The developability classification system: application of biopharmaceutics concepts to formulation development","volume":"99","author":"Butler","year":"2010","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2024.10.030_bib0048","unstructured":"Food and Drug Administration (FDA). Guidance for industry. Evaluation of gastric pH-dependent drug interactions with acid-reducing agents: study design, data analysis, and clinical implications. 2023."},{"issue":"5 Suppl","key":"10.1016\/j.xphs.2024.10.030_bib0049","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.5664\/jcsm.26929","article-title":"Insomnia: definition, prevalence, etiology, and consequences","volume":"3","author":"Roth","year":"2007","journal-title":"J Clin Sleep Med"},{"key":"10.1016\/j.xphs.2024.10.030_bib0050","unstructured":"Food and Drug Administration (FDA). Draft guidance. The use of physiologically based pharmacokinetic analyses \u2014 biopharmaceutics applications for oral drug product development, manufacturing changes, and controls. Guidance for industry. 2020."},{"key":"10.1016\/j.xphs.2024.10.030_bib0051","doi-asserted-by":"crossref","DOI":"10.1021\/acs.molpharmaceut.4c00526","article-title":"Parameterization of physiologically based biopharmaceutics models: workshop summary report","author":"Pepin","year":"2024","journal-title":"Mol Pharm"},{"issue":"5","key":"10.1016\/j.xphs.2024.10.030_bib0052","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1021\/acs.molpharmaceut.4c00202","article-title":"Physiologically based biopharmaceutics modeling (PBBM): best practices for drug product quality, regulatory and industry perspectives: 2023 workshop summary report","volume":"21","author":"Mackie","year":"2024","journal-title":"Mol Pharm"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354924004805?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354924004805?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T22:01:46Z","timestamp":1742680906000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354924004805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S0022354924004805"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2024.10.030","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biowaiver monographs for immediate-release solid oral dosage forms: Lemborexant","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2024.10.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Pharmacists Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}